Fundamental investigation aimed at EB virus-targeted therapy for nasal NK/T-cell lymphoma.

点击翻译按钮获取中文摘要

Nasal NK/T cell lymphoma is Epstein-Barr virus(EBV)-related and poor prognosis malignancy. In this study, we found that chemokine IP-10 (Interferon gamma-induced protein-10) was produced by EBV positive Nasal NK/T cell lymphoma cell lines, and the IP-10 enhanced invasive potential of the cells in autocrine manner. Moreover, we revealed that monocytes attracted by IP-10 enhanced proliferation and LMP-1 expression of the cells by cell-contact manner via membrane-bound IL-15. Currently, we are studying about CD70 and LFA-1, which can be regulated by EBV. On clinical studies, we are trying arterial infusion chemotherapy from superficial temporal artery in combination with radiotherapy for early stage nasal NK/T-cell lymphoma. Effect of the treatments was evaluated by serum EBV-DNA copy number, as well as local findings, CT, and MRI. All of 9 patients treated by this approach were in complete remission, and no sign of relapse has seen in the patients.